Novartis Institutes for BioMedical Research (NIBR) is the global pharmaceutical research organization for Novartis, committed to discovering innovative medicines that treat disease and improve human health.
Our longstanding commitment to understanding the underlying molecular basis of disease has enabled us to deepen our knowledge, and turn scientific insights into medical breakthroughs.
We bring new technologies to bear on understanding the fundamental science behind both normal and disease-related human biology.
We address unmet medical need in the developing world by focusing on neglected disease, such as malaria and Chagas.
On March 7th, 1996 Sandoz and Ciba-Geigy, the two Swiss-based chemical/life sciences giants, became Novartis.